2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
- Home
- Clinical Resources Search
- PQI: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
About this PQI
The purpose of this PQI is to discuss clinical considerations of epcoritamab (Epkinly®) treatment for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.
Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
PQI
PQI
PQI
PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma
Last Updated: 09/10/2026
PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
Last Updated: 09/10/2026
PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer
Last Updated: 05/15/2026
PQI: Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment
Last Updated: 04/24/2026
PQI in Action
PQI in Action
PQI in Action
PQI in Action
PQI in Action: Inavolisib (Itovebi) Patient Management
Last Updated: 08/01/2026
PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia
Last Updated: 06/30/2026
PQI in Action: Capivasertib (Truqap) Patient Management
Last Updated: 05/06/2026
PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)
Last Updated: 04/01/2026
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit: Elranatamab
Last Updated: 01/06/2026
Treatment Support Kit: Bispecific (T-Cell Engager)
Last Updated: 12/12/2025
Treatment Support Kit: Zanidatamab-hrii
Last Updated: 09/28/2025
Treatment Support Kit: Avutometinib and Defactinib
Last Updated: 08/06/2025
PQI
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
Last Updated: 09/10/2026
Fludarabine and Cyclophosphamide
Last Updated: 06/29/2026
Bendamustine
Last Updated: 06/29/2026
Tisagenlecleucel
Last Updated: 06/22/2026
Patient Education Sheet
PQI
Patient Education Sheet
Patient Education Sheet
Tafasitamab, Rituximab, and Lenalidomide
Last Updated: 09/14/2026
PQI: Tafasitamab-cxix (Monjuvi) for Relapsed/Refractory Follicular Lymphoma
Last Updated: 09/10/2026
Obinutuzumab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Last Updated: 09/08/2026
Obinutuzumab and Cyclophosphamide, Vincristine, and Prednisone
Last Updated: 09/08/2026
Patient Education Sheet
Patient Education Sheet
PQI in Action
Treatment Discussion Guides
Epcoritamab and R2
Last Updated: 08/14/2026
Epcoritamab and GemOx
Last Updated: 04/06/2026
PQI in Action: Epcoritamab (Epkinly) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Last Updated: 10/09/2025
Bispecific T-Cell Engagers in Non-Hodgkin Lymphoma: Treatment Discussion Guide
Last Updated: 04/24/2025
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
PQI
Melphalan Conditioning for Autologous Transplant
Last Updated: 09/29/2026
Carmustine, Etoposide, Cytarabine, and Melphalan
Last Updated: 09/29/2026
Talquetamab, Pomalidomide and Daratumumab/Hyaluronidase
Last Updated: 09/29/2026
PQI: Teclistamab-cqyv (Tecvayli) in Combination with Daratumumab and Hyaluronidase-fihj (Darzalex Faspro) for Relapsed Multiple Myeloma
Last Updated: 09/10/2026